Breaking the Cycle of Excess Mucus, Inflammation, and Infection
ARINA·1 is a novel, at-home nebulized therapy that restores overall lung health by clearing mucus, reducing inflammation, and inhibiting bacterial growth. Our initial focus is on individuals with prevention of BOS progression in lung transplant, non-CF bronchiectasis (NCFBE), and nontuberculous mycobacterial lung disease (NTM-LD).
General Questions About Clinical Trials?
What are clinical trials?
Am I required to participate in clinical trials?
What if I’m interested in participating?
Can I stop being in the clinical trial if I want to?
Is this drug safe to take?
Over 25 patient-years of clinical safety and efficacy data supported
by clean chronic toxicology data.
What are the different phases of a clinical trial?
Safety testing to ensure that therapy has an appropriate safety profile for a population.
Efficacy testing in a small number of patients to gain insight into the efficacy and further assess safety.
Large-scale efficacy testing in the target patient population. Phase 3 trials provide the key data on how well the drug works in a given population and allows for a company to submit the data for FDA approval for that population of patients.
Improves lung health by delivering ions directly to the airway
Restores innate immune defenses
Proven to decrease mucus, inflammation, and infection
Nebulized, at-home therapy
10-15 minute nebulization
In our target diseases, thick mucus often accumulates in the lungs and cannot be effectively cleared out of the airways, which leads to mucus plugging and difficulty breathing.